Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Céline Hélène Rouquayrol has worked on the following 11 EPO patent applications which have been published in the last five years:

EP12714163

FORMULATIONS COMPRISING 2 -AMINO- 2- [2- (4 - OCTYLPHENYL) ETHYL]PROPANE -1, 3 - DIOL

IPC classification:
A61K 9/16, A61K 31/137, A61P 37/06
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
PATENT GRANTED
EP12729907

WASH SOLUTION AND METHOD FOR AFFINITY CHROMATOGRAPHY

IPC classification:
C07K 1/22
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12756466

COMBINATIONS COMPRISING A S1P RECEPTOR MODULATOR

IPC classification:
A61K 31/135, A61K 31/137, A61K 31/343, A61K 31/4525, A61K 45/06, A61P 25/24
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12720757

METHOD OF TREATING VISION DISORDERS

IPC classification:
A61P 27/02, C07K 16/22
Applicant:
Novartis AG
Agent:
Multiple attorneys, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14163450

Solid oral composition comprising a S1P receptor agonist and a sugar alcohol

IPC classification:
A61K 9/20, A61K 9/48, A61K 31/137, A61P 25/00
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP13186359

S1P receptor modulators for treating multiple sclerosis

IPC classification:
A61K 31/137, A61K 31/397, A61P 37/06
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP13177175

Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators

IPC classification:
A61K 9/00, A61K 9/20, A61K 9/70, A61K 31/137
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14167553

Combinations comprising MGLUR modulators for the treatment of parkinson's disease

IPC classification:
A61K 31/404, A61K 31/4427, A61K 31/4545, A61K 31/465, A61K 31/4709, A61K 31/4725, A61K 45/06, A61P 25/16
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP14178519

Compound formulations of 2-amino-1,3-propanediol compounds

IPC classification:
A61K 9/00, A61K 31/133, A61K 47/10, A61P 37/00, A61P 37/06
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
APPLICATION WITHDRAWN
EP13701276

SYRINGE

IPC classification:
A61K 9/00, A61M 5/28, A61M 5/31, A61M 5/315
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP13753858

USE OF A VEGF ANTAGONIST IN TREATING OCULAR VASCULAR PROLIFERATIVE DISEASES

IPC classification:
A61K 38/17, A61K 47/48, A61P 27/02
Applicant:
Novartis AG
Agent:
Céline Hélène Rouquayrol, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS

Please Sign in to use this feature